NewsRoom Articles - Page 74 of 218

MondayJun 26, 2023 11:56 am

Virus Therapy Plus Radiation Could Improve Brain Tumor Treatment, Study Finds

University of Alberta researchers may have devised an extra-effective brain tumor treatment by combining radiation therapy with a cancer-targeting virus. The researchers found that the combination of both treatments was more effective at treating brain cancer in mice than taking the treatments separately, indicating that scientists could develop effective cancer treatments by combining existing therapies. Brain cancer is a deadly disease that is characterized by the development and spread of tumors in the brain and has exceedingly poor health outcomes. Like most cancers, brain tumors have no cure. Most treatment efforts involve killing off as many cancer cells as possible…

FridayJun 23, 2023 10:02 am

Why Women with MS See Decreased Symptoms When Pregnant

Most people with multiple sclerosis (MS) are women (74%), while men comprise only 24% of MS patients. Women are three times more likely to develop multiple sclerosis, and the National Multiple Sclerosis Society states that more women are developing the condition as time passes. Although we still haven’t figured out what exactly causes MS, researchers posit that factors such as stress, smoking, hormones such as estrogen, and inflammation may increase the risk of developing multiple sclerosis. Many women with the condition have noticed that their symptoms decrease when they are pregnant, with some reporting a significant reduction in symptoms during…

FridayJun 23, 2023 9:45 am

Genprex Inc. (NASDAQ: GNPX) CMO Discusses Recent Company Announcements in Bell2Bell Podcast Episode

Genprex Chief Medical Officer, Dr. Mark Berger, was featured in a recent Bell2Bell Podcast episode, where he discussed the company’s recent announcements In May, the company received Safety Review Committee (“SRC”) approval to advance to the Phase 2 expansion portion of its Acclaim-1 clinical trial of its lead candidate, REQORSA(R) Immunogene Therapy The Phase 1 dose escalation portion of the study showed that REQORSA(R) was generally well tolerated, and there were no dose-limiting toxicities; Genprex also reported encouraging evidence of efficacy in this portion In April, Genprex announced that its research collaborators presented in vivo mouse data showing that Genprex’s…

ThursdayJun 22, 2023 11:16 am

Armistice Capital LLC Cuts Stake in Shopify by 59%

Last week, a well-known hedge fund based in New York significantly reduced its stake in Shopify Inc. Shopify is a multinational, e-commerce company headquartered in Ontario, Canada. The company offers e-commerce solutions for micro, small and large businesses, allowing them to sell their services and products online without any hitches. The hedge fund in question, Armistice Capital LLC, is a global value-oriented and event-driven hedge fund that focuses primarily on the healthcare and consumer sectors. Armistice recently filed a report with the Securities & Exchange Commission reducing its position in Shopify by 59%. It is reported that the institutional investor…

ThursdayJun 22, 2023 10:30 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Gains Exclusive Development and Commercialization License from Max Planck for biobetter Anti-IL-17 Antibody

BiondVax just signed an exclusive worldwide license agreement with the Max Planck Society to develop and commercialize innovative NanoAb therapeutics for the treatment of psoriasis and psoriatic arthritis Part of an ongoing broad-based collaboration targeting therapies addressing diseases such as Covid-19, asthma, and macular degeneration Per BiondVax’s CEO, Amir Reichman, this exclusive license presents an exciting opportunity to develop a unique treatment for psoriasis BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products mainly for treating infectious and autoimmune diseases, just announced that it has signed an exclusive worldwide license agreement to develop…

WednesdayJun 21, 2023 11:14 am

Research Suggests Regulating Cholesterol Could Prevent Hair Loss

An estimated 85% of men will experience hair loss or male pattern baldness in their lifetimes. Even though we naturally shed and replace up to 100 strands of hair daily, this cycle is interrupted in men with male-pattern baldness, resulting in hair loss over time. Although genetics are typically the main driver for hair loss, it can also be caused by diseases such as anemia, scalp infections, chemotherapy or radiation treatments, stress and diet problems. Kerala University researchers have developed a treatment that could arrest the development of a rare type of hair loss called primary cicatricial alopecia (PCA). PCA…

TuesdayJun 20, 2023 11:45 am

Experimental Vaccine Brings Hope of Slowing Glioblastoma Tumor Regrowth

Of the more than 120 types of brain tumors that affect humans, glioblastomas are undoubtedly one of the deadliest. This is a type of cancer that originates from the spinal cord or brain cells before swiftly infiltrating and destroying healthy tissues. Glioblastoma patients have an average life expectancy of 14 to 16 months after diagnosis, and only 1% of them manage to live for at least 10 years after receiving their diagnosis. Given the extremely deadly nature of the condition, researchers have spent decades working on better and more efficient ways to diagnose, treat the condition and prevent glioblastomas from…

TuesdayJun 20, 2023 11:00 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Expands Focus with Development of New NanoAb Therapeutics

Biotechnology company BiondVax has entered into a collaboration with Max Planck Institute for Multidisciplinary Sciences (“MPG”) and the University Medical Center Göttingen (“UMG”) to develop innovative NanoAbs BiondVax enjoys an exclusive option for an exclusive worldwide license agreement at pre-agreed financial terms for additional NanoAbs discovered and characterized thereunder the RCA The company recently announced intent to develop innovative NanoAbs targeting immune system cytokines such as IL-17 for the potential treatment of psoriasis and psoriatic arthritis Analysts at Zacks Small-Cap Research laud the shift in focus to anti-IL-17 and have pegged the stock to reach $8 per share from current…

TuesdayJun 20, 2023 10:15 am

Genprex Inc. (NASDAQ: GNPX) CMO Video Discusses Advances in Company’s Fight Against Tumors

U.S.-based gene therapy developer Genprex, Inc. is dedicated to finding more effective and novel solutions for battling cancer (particularly lung cancers) and diabetes Genprex utilizes a propriety platform that encapsulates tumor-suppressing genes within lipid nanoparticles that are injected intravenously The company has received Fast Track designation from the U.S. Food and Drug Administration (“FDA”) for its two non-small cell lung cancer (“NSCLC”) programs using its drug candidate, REQORSA(R) Genprex also expects to begin a third trial using its REQORSA therapy against small cell lung cancer (“SCLC”) later this year The company recently used its proprietary nanoparticle delivery system, Oncoprex(R), in…

FridayJun 16, 2023 12:33 pm

Research Shows Autoimmune Ailments Rising

The European Alliance of Associations for Rheumatology has reported an influx in the prevalence of auto-inflammatory and autoimmune diseases. Autoimmune conditions are diseases that occur when the body’s immune system mistakes healthy tissues for harmful cells and attacks normal cells. There is currently no cure for autoimmune diseases, but patients can use various treatments to manage the conditions and minimize organ damage. Although the association posits that the increase in autoimmune cases may be due to environmental factors, researchers don’t have enough data to come to a concrete conclusion. A team of researchers from the EULAR analyzed nearly 20 of…